

***Diagnosis of Fatty Acid Oxidation Disorders by
Quantitative Determination of Carnitine and
Acylcarnitine***

By

Sahar Sabry Zaki

***Researcher Assistant in Biochemical Genetics Department
National Research Center
B. Ph. S, Ain Shams University, (2004)***

***A Thesis Submitted for the Partial Fulfillment of Master Degree in
Pharmaceutical Sciences (Biochemistry)***

Under supervision of

Dr. Hala Osman El-Mesellamy

***Professor and Head of Biochemistry Department;
Faculty of Pharmacy-Ain Shams University***

Dr. Amr Sobhi Gouda

***Assistant Professor and Head of Biochemical Genetics
Department; National Research Center***

***Biochemistry Department
Faculty of Pharmacy
Ain Shams University
2011***

Acknowledgement

Acknowledgement

I would like to thank my dear professor; ***Professor Dr. Hala Osman El-Mesllamy*** for giving me the great honor of working under her supervision and learning from her.

I am also indebted to ***Dr. Amr Sobhy Gouda*** who had done his best through his invaluable help, great support, and valuable time.

I can not forget ***Professor Dr. Ekram Fateen***; my first professor who taught me the importance of the Biochemical Genetics Science and how it can play a role in improving people life.

I would like to thank also the pediatricians in the genetics unit in the NRC for their help by referring all the suspected cases to our lab with giving the other clinical information about the patients.

My great thank, appreciation, and respect to all my colleagues in Biochemical Genetics Department in the NRC for their indefinite help and favors during working on this thesis.

Finally, I would like to thank and pray for all the studied children and their parents who allowed me to perform my study despite their sufferings but with a great hope in having a better life.

Sahar Sabry Zaki

List of Contents

List of Contents

<i>List of Abbreviations</i>	I-II
<i>List of Figures</i>	I - IV
<i>List of Tables</i>	I
<i>Aim of The Work</i>	1-2
 <i>Introduction and Review of Literature:</i>	 3
○ Classification of fatty acid oxidation disorders	5
I- Defects in carnitine cycle ...	5 - 12
II- Defects in β -oxidation spiral	12 - 22
III- Genetic disorders of ketogenesis	23 - 26
○ Biochemical presentation in fatty acid oxidation disorders	27
○ Inborn errors of metabolism and neonatal screening	28 - 30
○ Acylcarnitine profile	31
○ Mass spectrometric analysis of acylcarnitine profile	31 - 32
○ Tandem mass spectrometry technique	33 - 35
 <i>Subjects & Methods:</i>	 36
○ Subjects	36
○ Samples	37
○ Methods	38
1. Measurement of blood glucose	38
2. Detection of urinary ketone bodies	39
3. Measurement of NH_3	40
4. Measurement of lactate	41
5. Measurement of transaminases	43
6. Measurement of CK level	45

7. Determination of urinary organic acids.....	46
8. Determination of acylcarnitines in dried blood spot.....	46
- Chemicals.....	46
- Equipments.....	47
- Derivatization of acylcarnitines.....	47
- Electrospray ionization mass analysis.....	48
- Method validation.....	48
- Calibration.....	48
- Quantitation of acylcarnitines.....	49
- Reference ranges.....	50
-Testing personnel.....	51
Results	52
○ Data of the study group:.....	52
1. Age, sex, consanguinity and history of sibling deaths.....	52 - 53
2. Clinical presentation and manifestations in the study group.	54 - 55
3. Laboratory findings in the study group.....	56 - 58
○ Data of the diagnosed patients among the study group according to their ACP:.....	59
1. Consanguinity and History of sibling deaths.....	59 - 61
2. Clinical Presentation and manifestations.....	62 - 64
3. Laboratory findings in the diagnosed patient groups.....	64 - 71
○ LC/MS/MS Chromatograms.....	71
1. Acylcarnitine profiles of normal subjects and diagnosed patients.....	74 - 78
2. Organic acid profiles of normal subjects and diagnosed patients.....	79 - 82

<i>Discussion</i>	83 – 96
<i>Summary</i>	97 - 98
<i>Conclusion</i>	99 - 101
<i>References</i>	102 - 115
<i>Appendix</i>	I - XXXVIII
<i>Arabic summary</i>	أ – ت

*List of
Abbreviations*

List of Abbreviations

ACP(s)	Acylcarnitine profile(s)
AC(s)	Acylcarnitine(s)
Arb	Arbitrary unit (flow unit)
4-AP	4-aminophenazone
BBB	Blood brain barrier
CAT	Carnitine acetyl transferase
CACT	Carnitine/acylcarnitine translocase
CK	Creatine kinase
CMR	Cardiac magnetic resonance
CoQ10	Complex Q10 (respiratory chain)
CPT	Carnitine palmitoyl transferase
DCs	Dicarboxylic acid(s)
DBS	Dried blood spot
DHA	Docosahexaenoic acid
DNPH	Dinitrophenylhydrazine
ESI	Electrospray ionisation
ETF	Electron transfer flavoprotein
FAB-MS/MS	Fast atom bombardment mass spectrometry
FAODs	Fatty acid oxidation disorders
FFAs	Free fatty acids
GA	Glutaric aciduria
GLDH	Glutamate dehydrogenase
GO	Glucose oxidase
HMG-CoA	Hydroxy-3-methylglutaryl-coenzyme A
IEM	Inborn error(s) of metabolism
ISTD	Internal standard

LCADD	Long chain acyl-CoA dehydrogenase deficiency
LCHAD	Long chain L-3 hydroxyacyl CoA dehydrogenase deficiency
LDH	Lactate dehydrogenase
LO	Lactate oxidase
m/z	Mass to charge ratio
MADD	Multiple acyl CoA dehydrogenase deficiency
MCAD	Medium chain acyl CoA dehydrogenase deficiency
MCD	Muscle carnitine deficiency
MMA	Methylmalonic aciduria
MS/MS	Mass/mass spectrometry
MCT	Medium chain triglycerides
OCTN2	Organic cation/ carnitine transporter novel 2
PCA	Principal component analysis
PDH	Pyruvate dehydrogenase
POD	Peroxidase
RI	Renal insufficiency
RF	Radio frequency
RPE	Retinal pigment epithelium
RT	Retention time
SCADD	Short chain acyl CoA dehydrogenase deficiency
SCD	Secondary carnitine deficiency
SCHAD	Short chain hydroxyacyl CoA dehydrogenase deficiency
SIDS	Sudden infant death syndrome
SPSS	Statistical package for social science
TFP	Trifunctional protein
TIC	Total ion current
VLCADD	Very long chain acyl CoA dehydrogenase deficiency
VPA	Valproic acid

List of Figures

List of Figures

Figure (1)	An overview of the carnitine cycle and mitochondrial fatty acid oxidation.....	4
Figure (2)	Autosomal recessive inheritance of FAODs.....	5
Figure (3)	Schematic demonstration of mitochondrial fatty acid β -oxidation and effects of LCHAD deficiency.....	14
Figure (4)	Dehydrogenase defects in MADD.....	21
Figure (5)	Schematic demonstration presenting the site of the blockage in the ketogenesis through the metabolism of fatty acids and leucine.....	23
Figure (6)	Schematic demonstration presenting the site of the blockage in the ketogenesis through the metabolism of fatty acids	26
Figure (7)	Schematic diagram displays the biochemical causes of the main clinical features in FAODs.....	27
Figure (8)	Flowchart of newborn screening.....	29
Figure (9)	Schematic summary of targeted and nontargeted metabolomics methods.....	30
Figure (10)	An outline of the automated liquid chromatography-mass spectrometry (LC-MS) analysis of the extracted biological samples.....	32
Figure (11)	Schematic diagram explaining the steps of detection of an analyte within a sample injected to a tandem mass spectrometry.....	33
Figure (12)	Basic scheme of a tandem mass spectrometer.....	34
Figure (13)	Standard electrospray ionisation source.....	35
Figure (14)	ESI process and ions generation.....	35
Figure (15)	A peak of a certain AC species at a defined RT with a specific intensity integrated quantitatively to calculate its area.....	49

Figure (16)	Calibration curve of ACs concentration vs. the area ratios.....	50
Figure (17)	Chart represents the distribution of the study group according to sex from total 150 high risk patients.....	52
Figure (18)	Chart represents the percentage of consanguinity in high risk patients from total 150 high risk patients.....	52
Figure (19)	Chart represents the percentage of high risk patients had history of sibling deaths from total 150 high risk patients.....	53
Figure (20)	Chart represents the percentage of high risk patients had chronic or acute clinical presentation from total 150 high risk patients.....	54
Figure (21)	Chart represents the percentage of high risk patients in relation with the clinical manifestations presented from total 150 high risk patients.....	55
Figure (22)	Chart represents the percentage of high risk patients had normal ACP and those with abnormal ACP from total 150 high risk patients.....	58
Figure (23)	Chart represents the percentage of high risk patients had normal organic acid profile and those with abnormal ones from total 150 high risk patients.....	58
Figure (24)	Chart represents the no. of diagnosed patients in the study group.....	59
Figure (25)	Chart of the percentage of consanguinity in the diagnosed patients from total 37 patients.....	60
Figure (26)	Chart represents the percentage of diagnosed patients had history of sibling deaths from total 37 patients.....	61
Figure (27)	Chart represents the percentage of diagnosed patients had chronic or acute clinical presentation from total 37 patients.....	62
Figure (28)	Chart represents the percentage of the clinical manifestations presented in diagnosed patients from total 37 patients.....	64
Figure (29)	Chart represents the different NH ₃ levels in each diagnosed FAOD.....	65
Figure (30)	Chart represents the different lactate levels in each diagnosed FAOD.....	66

Figure (31)	Chart represents the different transaminases level in each diagnosed FAOD.....	66
Figure (32)	Chart represents the different CK enzyme levels in each diagnosed FAOD.....	66
Figure (33)	Chart represents the mean of levels of MCADD diagnostic ACs.....	68
Figure (34)	Chart represents the mean of C ₀ & C ₂ levels in RI-patients undergoing hemodialysis therapy.....	68
Figure (35)	Chart represents the mean of levels of C ₃ & C ₅ of patients on chronic VPA therapy.....	68
Figure (36)	Chart represents the levels of LCHADD diagnostic ACs.....	70
Figure (37)	Chart represents the levels of MADD diagnostic ACs.....	70
Figure (38)	Chart represents the levels of GA I diagnostic ACs.....	70
Figure (39)	Chart represents the levels of MMA diagnostic ACs.....	71
Figure (40)	LC/MS/MS chromatograms and the fragmentation pattern of ACs.....	72
Figure (41)	Total ion current (TIC) of a control DBS displays the specific RT of each AC mass.....	74
Figure (42)	Ion signals at representative masses of several protonated masses [M+H] ⁺ ACs and their ISTD butylesters in control DBS.....	74
Figure (43)	Ion signals at representative masses of protonated masses [M+H] ⁺ medium chain AC butylesters diagnostic for MCADD.....	75
Figure (44)	Ion signals of protonated masses [M+H] ⁺ long chain hydroxy AC butylesters diagnostic for LCHADD.....	75
Figure (45)	ACP with an elevation in almost all ACs species; short chain-, medium chain-, and long chain ACs, diagnostic for MADD.....	76
Figure (46)	ACP of a RI-patient before hemodialysis session.....	76
Figure (47)	ACP of a RI-patient after hemodialysis session.....	77
Figure (48)	ACP of a patient was on chronic (Depakine®) therapy.....	77
Figure (49)	Ion signals of protonated masses [M+H] ⁺ of glutaryl- and butyryl carnitine butylesters, diagnostic for GA I.....	78
Figure (50)	Ion signals of protonated masses [M+H] ⁺ of propionyl-, butyryl-, and hydroxy butyrylcarnitine butylesters, diagnostic for MMA.....	78

Figure (51)	A qualitative full-mass chromatogram representative for a normal OAP.....	79
Figure (52)	A qualitative full-mass chromatogram of OAP of an MCADD-patient.....	80
Figure (53)	A qualitative full-mass chromatogram representative for OAP of LCHADD-patient.....	80
Figure (54)	A qualitative full-mass chromatogram representative for OAP of GA II-patient.....	81
Figure (55)	A qualitative full-mass chromatogram representative for OAP of GA I-patient.....	81
Figure (56)	A qualitative full-mass chromatogram representative for OAP of MMA-patient.....	82